Sorafenib and Docetaxel in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Previous Hormone Therapy

• Status: Completed
• Trial end date: 2011-02-02
• Target enrollment: 0
• Participant gender: Male

Summary

RATIONALE: Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving sorafenib together with docetaxel may kill more tumor cells.

PURPOSE: This phase II trial is studying giving sorafenib together with docetaxel to see how well it works in treating patients with metastatic androgen-independent prostate cancer.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Abramson Cancer Center of the University of Pennsylvania; University of Pennsylvania
• Collaborator: National Cancer Institute (NCI)
• Treatments: Docetaxel; Sorafenib

Criteria

DISEASE CHARACTERISTICS:

• Histologically or cytologically confirmed adenocarcinoma of the prostate

• Androgen-independent disease

• Metastatic disease measured by clinical or radiological evidence

• Disease progression during hormonal therapy, defined by one or more of the following:

• Increasing serum PSA levels on ≥ 2 measurements at least two weeks apart

• Progressive measurable disease (by RECIST criteria) independent of PSA

• Bone scan progression with at least one new lesion

• Must be receiving primary androgen ablation therapy with gonadotropin-releasing hormone agonists (GnRH) as maintenance therapy unless surgically castrated

• Serum PSA > 5 ng/mL

• No history of brain metastasis or leptomeningeal disease

PATIENT CHARACTERISTICS:

• ECOG performance status 0-1

• WBC ≥ 3,000/mm³

• Absolute granulocyte count ≥ 1,500/mm³

• Platelet count ≥ 100,000/mm³

• Creatinine ≤ 2.0 times the upper limit of normal (ULN)

• Total bilirubin normal

• AST and ALT ≤ 5 times ULN

• INR ≤ 1.5 and PTT normal (before the start of chronic anticoagulation)

• Fertile patients must use effective contraception during and for ≥ 3 months after completion of study therapy

• No symptomatic neuropathy grade ≥ 2

• No HIV positivity

• No history of cancer except basal cell or squamous-cell skin cancer within the past 5 years

• No history of deep vein thrombosis or pulmonary embolism within the past year

• No serious medical illness including, but not limited to, any of the following:

• Ongoing or active infection requiring parental antibiotics

• Clinically significant cardiovascular disease (e.g., uncontrolled hypertension, recent myocardial infarction, unstable angina)

• NYHA class II-IV congestive heart failure

• NYHA class II-IV peripheral arterial vascular disease within the past year

• Psychiatric illness or social situations that would limit study compliance

• No history of severe hypersensitivity reaction to docetaxel or other drugs formulated with polysorbate 80

PRIOR CONCURRENT THERAPY:

• See Disease Characteristics

• At least 4 weeks since prior flutamide or nilutamide (6 weeks for bicalutamide)

• At least 4 weeks since prior radiotherapy

• Must have radiographic evidence of progression of any lesion that has received radiotherapy in order for that lesion to constitute measurable disease or be considered a measured target lesion

• Prior vaccine therapy allowed

• Prior and/or concurrent zoledronic acid therapy allowed

• No prior cytotoxic chemotherapy

• No prior radioisotope therapy

• No concurrent cytochrome P450 enzyme-inducing antiepileptic drugs (e.g., phenytoin, carbamazepine, or phenobarbital)

• No concurrent rifampin or St. John's wort

• No concurrent inhibitors of CYP3A, including any of the following:

• Ketoconazole

• Voriconazole

• Itraconazole

• Fluconazole

• Cimetidine

• Clarithromycin

• Erythromycin

• Troleandomycin

• Grapefruit juice

• No concurrent combination antiretroviral therapy for HIV-positive patients

• Concurrent bisphosphonate therapy allowed